Catalyst brief · Phase 2/3 readout · 26 days
Selinexor (combination therapy): Selinexor (combination therapy) in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc · $KPTIQ · built 19 Nov 2026 from 18 sourced facts · open on the radar
Analyst desk
Five AI analysts read the facts below. Each sentence shows the facts it rests on.
Trial design
- The trial's double-blind and randomised design, with a main goal of Overall Response Rate, will provide a convincing result if the outcome is positive, as these elements help reduce bias and ensure reliable data. F3 F4 F5
- The trial's large size, with a plan to enrol 501 patients, will also contribute to the reliability of the results, as it will provide a more precise estimate of the treatment's effect. F2
- The fact that the trial has 6 study arms may allow for a more detailed comparison of different treatment regimens, but it also increases the complexity of the trial and may make it more challenging to interpret the results. F7
Base rates
- Historically, 47.7% of Phase 3 programmes in oncology moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F12
- The company's record shows that 100% of its active Phase 2 and 3 trials have had their dates moved back by more than 6 months. F13
- The DataCutoff timing model estimates this trial will finish close to its registry date. F11
- On average, KPTIQ's past trial-result days have had an absolute share move of 26.8%, which is a historical average and not a prediction for this trial. F14
The case for
The case against
- The trial's complexity, with 6 study arms, may make it challenging to interpret the results and could potentially lead to delays or difficulties in achieving a conclusive outcome. F7
- Although the DataCutoff timing model estimates this trial will finish close to its registry date, the company's past performance raises concerns about its ability to meet deadlines. F11 F13
Open questions
- Will the Overall Response Rate meet the expected outcome based on the Lugano Criteria 2014?
- How will the results from the 6 study arms be interpreted in terms of treatment efficacy?
- Will the trial complete on time, given KPTIQ's history of delaying trial dates?
8 AI sentences were removed by the fact check.
The facts
The trial
- F1Selinexor (combination therapy) is a Phase 2/3 trial of Selinexor (combination therapy) in Relapsed/Refractory Diffuse Large B-cell Lymphoma, sponsored by Karyopharm Therapeutics Inc (KPTIQ). source ↗
- F2The trial plans to enrol 501 patients; the target first registered was 492. source ↗
What counts as success
- F3Main goal as written in the registry: Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014. source ↗
- F4Blinding: double blind. source ↗
- F5Allocation: randomised. source ↗
- F6The main goal is measured over: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization). source ↗
- F7Number of study arms: 6. source ↗
When
- F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
- F10That date is 16.0 months later than the date first registered for this trial (Aug 2025). source ↗
- F11The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗
Recruitment
- F8The registry lists 38 sites. source ↗
Base rates
- F12Historically 47.7% of Phase 3 programmes in oncology (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
- F13100% of KPTIQ's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗
- F14KPTIQ has had 5 past trial-result days on record, with an average absolute share move of 26.8%. source ↗
Money, insiders and FDA
- F15KPTIQ reported $65M in cash and short-term investments as of 30 Jun 2026 (10-Q). source ↗
- F16At the last 12 months' rate of spending (about $5M a month) that cash lasts about 12 months, to around Jun 2027, which is after the registry's primary completion date. source ↗
- F17Insiders made 3 unplanned open-market sales in the last 90 days, totalling $2K. source ↗
Rivals
- F18HCM is running a Phase 3 trial of HMPL-760 in the same condition, with a registry date of 30 Apr 2028. source ↗
How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.